BERN. Basel's pharmaceutical industry has opened a frontal campaign against the way Switzerland sets medicine prices, arguing that the country's reliance on international price comparisons is quietly eroding the research base that fills the canton's tax coffers. The pushback, coordinated through industry associations and sympathetic parliamentarians, targets a tool the Federal Office of Public Health has used for two decades to keep the national drugs bill in check.
Under the current system, the office benchmarks the price of new medicines against a basket of nine reference countries and applies an additional therapeutic comparison before a drug is admitted to the list of products reimbursed by compulsory insurance. The industry contends the method has drifted far from its original purpose, producing Swiss prices so low that manufacturers now delay or skip launching products here.
The numbers the industry cites are striking. It claims that of the innovative medicines approved in the European Union over the past five years, barely two thirds are available to Swiss patients within eighteen months, and that the gap is widest in oncology. Patient advocates confirm parts of that picture, pointing to individual cancer drugs that reached German clinics a year before Swiss ones. The Federal Office of Public Health disputes the industry's counting method but acknowledges delays for certain products.
The counterargument, made by insurers and the price watchdog, is that Switzerland still pays among the highest medicine prices in the world, roughly 9 per cent above the European median on comparable products. They note that pharmaceuticals account for about a tenth of all basic insurance costs, and that every concession flows directly into the October premium letter. The drugs bill for basic insurance reached roughly CHF 9 billion last year.
The cantons have entered the fray on both sides. Basel-Stadt and Basel-Landschaft, home to the two global champions that anchor Pharma Valley, warn that tens of thousands of jobs and a fifth of regional exports depend on a hospitable pricing climate. The two Basel cantons together collect an estimated CHF 3 billion a year in taxes from the sector and its suppliers. Cantonal health directors elsewhere reply that their hospital budgets cannot absorb open ended price demands.
A spokesperson for the insurers' association framed the dispute as a question of who bears risk. “Innovation deserves reward, but the premium payer is not a venture capital fund,” the spokesperson said.
The industry has floated alternatives, including confidential rebates of the kind used in Britain and outcome based contracts in which manufacturers refund part of the price when a drug fails to deliver. Insurers are cautiously receptive to the second idea, which has already been piloted for a handful of gene therapies costing more than a million francs per patient. Such arrangements now cover products with a combined annual cost of around CHF 500 million.
Critics within the research community itself urge perspective. Health economists at the universities of Basel and Zurich note that list prices are only one factor in launch decisions, and that Switzerland's small market and three language regions impose costs that have nothing to do with the comparison basket.
The political path runs through the health ministry's next revision of the reimbursement ordinance, due for consultation early next year. Parliament's health commissions have signalled interest in a compromise: faster provisional admission for breakthrough therapies, paired with mandatory price reviews after three years. A parliamentary motion demanding a six month deadline for reimbursement decisions is also pending.
For households, the stakes are concrete if indirect. Faster access to new cancer drugs would change individual lives immediately, while a general loosening of price discipline would show up within two years in premiums. The reverse is also true: tougher comparisons save money quietly, one delayed launch at a time.
Both sides claim to speak for patients, and both have a point. The autumn consultation will show whether Bern can reward the test tubes of Basel without emptying the wallets of policyholders.
The historical irony is not lost on older observers. Switzerland introduced the reference basket in the early 2000s under pressure from the same insurers now defending it, and the industry accepted it then as the price of predictable reimbursement. Two decades on, both sides are litigating the details of a compromise that was never meant to be permanent.